Rigel Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Rigel reported 3rd quarter 2026 net product sales of $72.3 million, up 13% year over year, and total revenues of $80.9 million.
- Net product sales were $46 million for Tavalisse, up 3%; $9.9 million for Reslydia, up 20%; $9.8 million for Gavretto, down 11%; and $6.6 million for Vepanu, reflecting approximately 6 weeks of commercial availability.
- Vepanu became commercially available in the U.S. on August 13th, was shipped to over 100 patients and clinics during Q3, and most patients who started in August had received a first refill by quarter end.
- Vepanu's estimated prior authorization approval rate was 88%; the median time to fill through specialty pharmacies was 4 days.
- Collaboration revenues were $8.6 million, total cost and expenses were $63.8 million, and net income was $13.2 million, compared with net income of $27.9 million in the same period of 2025.
- Rigel ended the quarter with $99.3 million in cash, cash equivalents, and short-term investments, compared with $155 million as of the end of 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel, and Corporate Secretary. Thank you, Mr. Furey. You may begin.
Thank you. Welcome to our third quarter 2026 financial results conference call. The financial press release for the third quarter 2026 was issued earlier today and can be viewed along with the slides for this presentation in the news and events section of our investor relations site on rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for commercial, regulatory, product development, and other business activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found on our most recent annual report on Form 10-K for the year ended December 31, 2025, on file with the SEC, and subsequent filings with the SEC, including our Q3 quarterly report on Form 10-Q with the SEC.
Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances, except as required by law. At this time, I would like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez.
Raul? Thank you, Ray, and thank you all for joining us today.
Also joining me on the call are Dave Santos, our Chief Commercial Officer, Dr. Alison Hannah, our Chief Medical Officer, and Dean Schorno, our Chief Financial Officer. Before we begin, I'd like to share a few key highlights from the quarter. We delivered over $72 million in net product sales, our highest ever, and another profitable quarter. This while taking important steps towards Rigel's next phase of growth. VEPPANU, Rigel's fourth commercial product, is now available in the U.S. with an encouraging start to its launch, and we continue to advance R289 towards its next stage of development. I'll start with an overview of this progress before the team takes you through the details. Moving to slide four. VEPPANU became commercially available in the U.S. on August 13 and generated $6.6 million in net product sales through the end of the third quarter.
Following the close of the global in-license agreement in June, our team moved quickly to initiate launch activities, leveraging our established commercial and medical infrastructure to engage physicians and build awareness ahead of commercial availability. Within just two months of closing the transaction, VEPPANU was successfully integrated into our existing distribution network and ready for commercial launch. During Q3, we shipped VEPPANU to over 100 patients and clinics. Encouragingly, the majority of the patients who received VEPPANU during the early weeks of launch had already refilled their prescriptions by quarter end. We also have strong payer coverage, with patients able to access VEPPANU through either formulary coverage or through the exception process.
In addition, we are seeing positive engagement with healthcare providers, with our efforts focused on high-decile prescribers. As the first and only FDA-approved PROTAC therapy, or proteolysis-targeting chimera, VEPPANU offers a new mechanism of action and an important treatment option for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Our focus now is on building awareness of its differentiated mechanism and clinical data, then translating this into adoption through multifaceted campaigns. Dave will share more about our early launch experience and plans shortly. Overall, we are excited by VEPPANU's early launch performance and believe it has the potential to be Rigel's largest sales contributor. On slide five, we outline our transformational growth strategy. The VEPPANU launch is a clear example of this strategy in action. We identified a differentiated late-stage asset in oncology and leveraged our established infrastructure to rapidly integrate and launch the product.
We intend to build on that approach as we continue to grow our portfolio of four commercial products and evaluate additional in-license opportunities. At the same time, we are investing in our development pipeline, led by R289, our dual IRAK1 and four inhibitor, which is currently being evaluated in a phase I-B clinical studies in patients with lower-risk MDS. We look forward to presenting updated data on this study at the ASH meeting in December. Financial discipline is what connects these strategic objectives. Our growing commercial business enables us to invest in opportunities with substantial long-term potential while maintaining our focus on profitability. We believe this combination of commercial execution, pipeline advancement, and financial discipline sets us apart and positions Rigel well for its next phase of growth. Slide six highlights our track record of commercial growth, and more importantly, the opportunities ahead for Rigel.
We grew our net product sales by a compound annual growth rate of approximately 35% annually since 2022. Looking into the future, we have two sequential engines of significant growth, VEPPANU and then R289. We are encouraged by VEPPANU's early performance and see significant potential in a large and growing market. Turning to R289, we continue to advance its development in patients with lower-risk MDS, a disease with significant unmet medical need. At the ASH meeting in December, we plan to present updated data from the phase I-B study, including preliminary efficacy data from the dose expansion phase. We also remain on track to complete enrollment and select the recommended phase II dose for future development by the end of 2026. We plan to initiate a registrational program in lower-risk MDS next year and believe that R289 has the potential to be a billion-dollar-plus commercial opportunity in this indication.
Together, VEPPANU and R289 offer significant commercial potential, and they are central to our plans to substantially expand Rigel's business over the coming years and drive long-term shareholder value. With that, I'll turn the call over to Dave to discuss our commercial performance and the latest on the VEPPANU launch.
Dave? Thank you, Raul. On slide eight, you'll see our four commercial products: VEPPANU, TAVALISSE, REZLIDHIA, and GAVRETO.
Moving to slide nine, our net product sales were $72.3 million for the third quarter of 2026, an increase of 13% compared to the third quarter of 2025, primarily driven by the addition of VEPPANU during the third quarter. Year-to-date 2026, we reported $194.2 million in net product sales, an increase of 17% compared to the same period of 2025. As Raul mentioned, we're extremely excited that VEPPANU is commercially available, and we reported $6.6 million in net product sales for the third quarter, which reflects approximately six weeks of product availability. I'll talk more about VEPPANU in a few minutes. For TAVALISSE, we generated $46 million in net product sales, an increase of 3% compared to the third quarter of 2025.
Eight years after launch, TAVALISSE continues to be a strong and consistent contributor to our portfolio. For REZLIDHIA, we reported $9.9 million in net product sales, an increase of 20% compared to the prior year period. We continue to believe REZLIDHIA adoption will grow in the community setting and in the post-venetoclax patient population. Finally, for GAVRETO, we delivered $9.8 million in net product sales, a decrease of 11% compared to the third quarter of 2025. GAVRETO continues to be a stable, contributing product in our portfolio. Overall, we are very pleased with our third-quarter results. While VEPPANU is now our lead focus, we remain committed to supporting TAVALISSE, REZLIDHIA, and GAVRETO. Importantly, the engagement of our field team has had around VEPPANU is opening doors to more accounts, which also creates opportunities to support our other products where there are appropriate patients.
Moving to slide 10, we generated $8.6 million in revenues from collaborations in the third quarter, driven primarily by the availability of TAVALISSE in global markets. TAVALISSE is commercially available in key European countries under the brand name TAVLESSE, in Japan and South Korea, in Canada and Israel, and in Mexico through our partners, Grünenthal, Kissei, Medison, and Knight. Knight also announced regulatory approval of TAVALISSE in Colombia in September and the launch of TAVALISSE in Brazil in October. Our partners continue to pursue regulatory approvals for TAVALISSE in new markets, and we are pleased that access to TAVALISSE continues to spread outside the U.S. For REZLIDHIA, our partners Kissei and Dr. Reddy's are advancing olutasidenib in their territories. I'll now turn to VEPPANU.
Before I get into the commercial launch, let me briefly remind you of the ER-positive, HER2-negative, ESR1-mutated advanced or metastatic patient opportunity, which you can see on slide 12. Of approximately 170,000 U.S. metastatic breast cancer patients, about 119,000 have ER-positive, HER2-negative disease. Prior endocrine and CDK4/6 therapy drives ESR1 resistance in about 40% of patients. Upon ctDNA testing, roughly 60%, corresponding to around 26,000 patients, are diagnosed with ESR1-mutated disease. Most of these patients are in the second or later line setting, resulting in about 20,000 patients with a critical unmet need in second line and later ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. This represents a U.S. market opportunity of $1 billion plus. I am now on slide 13. Resistance driven by ESR1 mutations continues to be a challenge for metastatic breast cancer patients, and ER degradation is an important therapeutic strategy for addressing these mutations.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
